TABLE 4.
Characteristics of studies.
| Studies | Subgroup | Regiments | Eradication rate (ITT/PP, %) | Adverse events rate (%) | Compliance (%) |
|---|---|---|---|---|---|
| Yang et al., 2019a | DT (116) Control (116) | E 20 mg qid + A 750 mg qid*14 d E 20 mg bid + B 1 g bid + A 1 g bid + C 500 mg bid*14 d | 87.9/91.1 89.7/91.2 | 6.3 22.8 | 96.6 98.3 |
| Song et al., 2020 | DT (380) Control (380) | E 20 mg qid + A 750 mg qid*14 d E 20 mg bid + B 220 mg bid + A 1 g bid + C 500 mg bid*14 d | 87.1/92.4 80.5/87.8 | 17.6 25.5 | 96.3 92.3 |
| Gao et al., 2020b) | DT (198) | R 10 mg tid + A 1000 mg tid*14 d | 90.9 | 11.1 | — |
| Yu et al., 2019 | DT (80) Control (80) | E 40 mg bid + A 1000 mg tid*14 d E 40 mg bid + A 1000 mg tid + B 220 mg bid *14 d | 88.8/93.3 92.5/96.1 | 11.3 8.8 | 98.7 97.5 |
| Zhang et al., 2020 | DT (104) Control (104) | E 20 mg qid + A 750 mg qid*10 d E 20 mg qid + A 1000 mg tid*14 d | 79.8/81.3 83.5/86.4 | 5.9 5.0 | 97.1 97.1 |
| Hu et al., 2017 | DT (87) DT (87) Control (89) | R10 mg qid + A 750 mg qid*14 d R 20 mg qid + A 750 mg qid*14 d E 20 mg bid + B 220 mg bid + A 1 g bid + C 500 mg bid*14 d | 78.1/79.1 81.6/83.5 84.3/86.2 | 3.4 5.7 11.2 |
98.9 97.7 97.8 |
| Shen et al., 2022 | DT (496) Control (475) | E 20 mg qid + A 750 mg qid*14 d E 20 mg bid + B 220 mg bid + A 1 g bid + C 250 mg bid*14 d | 88.3/91.6 85.2/90.6 | 13.3 28.2 | 99.2 99.2 |
| Zou et al., 2021 | DT (104) Control (116) | E 20 mg qid + A 750 mg qid*10 d E 20 mg qid + A 750 mg qid*14 d | 78.4/80.0 89.7/92.9 | 6.8 5.7 | 80.0 92.9 |
| Tai et al., 2019 | DT (115) Control (114) | E 40 mg qid + A 750 mg qid*14 d E 40 mg bid + M 500 mg bid + A 1 g bid + C 250 mg bid*14 d | 91.7/95.7 86.7/92.0 | 9.6 23.0 | 100 100 |
Abbreviations: A, amoxicillin; B, bismuth; C, clarithromycin; DT, dual therapy; E, esomeprazole; ITT, intention-to-treat analysis; L, levofloxacin; M, metronidazole; O, omeprazole; PP, per-protocol analysis; R, rabeprazole; T, tetracycline.